Monday 19 February 2018
Contact US    |    Archive
Reuters
5 months ago

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

BRIEF

 | 

Reata

 | 

Pharma

 | 

receives

 | 

orphan

 | 

drug

 | 

designation

 | 

for

 | 

Omaveloxolone

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
USA